Table 4 Optimal sensitivity and specificity as determined by Youden’s index calculation, based on cohort 2, comparing untreated (P)VRL with all other aetiologies.
| Protein | Youden’s index | Sensitivity | Specificity | AUC | Cut‐off value |
|---|---|---|---|---|---|
| (P)VRL versus other aetiologies | |||||
| IL‐10/IL‐6 ratio | 1.00 | 1.00 | 1.00 | 1.00 | 0.69 |
| ISOLD | 1.00 | 1.00 | 1.00 | 1.00 | ‐9.88 |
| IL‐10 | 1.00 | 1.00 | 1.00 | 1.00 | 6.13 |
| CD70 | 0.60 | 0.60 | 1.00 | 0.79 | 3.58 |
| EZR | 0.60 | 0.60 | 1.00 | 0.78 | 6.21 |
Top five discriminative biomarkers based on Youden’s index calculations on cohort 1.
(P)VRL = primary vitreoretinal lymphoma, AUC = area under the curve.